Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple fixed-combination ophthalmic solution versus COMBIGAN for intraocular pressure reduction in open-angle glaucoma or ocular hypertension
RBR-3crsfjPhase 3Not yet recruiting
- Sponsor
- Laboratório Daudt
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dorzolamide, brimonidine, timolol and brimonidine tartrate + timolol maleate in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Laboratório Daudt. Primary endpoints: Efficacy and Safety. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
dorzolamidebrimonidinetimololbrimonidine tartrate + timolol maleate
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on RBR-3crsfj.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3crsfj.